HIGHBuilt-inProduct / Revenue mix
livestock sector
“10-K Item 1: 'Our business is currently concentrated in the livestock sector.'”
PAHC · Concentration risk · 10-K extracted
Phibro Animal Health Corporatio (PAHC) concentration risks
Updated
The most significant concentration Phibro Animal Health Corporatio discloses is livestock sector, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Phibro Animal Health Corporatio’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 4 disclosed concentrations
HIGH1
MEDIUM3
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMBuilt-inProduct / Revenue mix
antibacterials and other related products
“10-K Item 1A: 'a material portion of our sales and gross profits are generated by antibacterials and other related products'”
MEDIUMBuilt-inRegulatory
FDA approval of Mecadox (carbadox)
“10-K Item 1A: 'the potential FDA withdrawal of approval of our Mecadox® (carbadox) product'”
MEDIUMBuilt-inGeographic
Israeli and Brazilian operations
“10-K Item 1A: 'our dependence on our Israeli and Brazilian operations'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-10-18Phibro's concentration profile is dominated by a structural one: the business is concentrated in the livestock sector, a high-share exposure that the company cannot diversify away from without changing what it is. Within that sector, a material portion of sales and gross profits comes from antibacterials and other related products, a medium-share exposure that ties earnings to a single product family and to the regulatory and public-health debate surrounding it. The remaining exposures are more specific. The potential FDA withdrawal of approval of Mecadox (carbadox) is a medium-share, regulator-driven risk, and the dependence on Israeli and Brazilian operations is a medium-share geographic exposure. Both are structural features of how the company is organized rather than counterparty-specific dependencies. Taken together, the sector and product concentrations are the ones that could move the verdict, because they are correlated: a shift in livestock demand or in antibacterial regulation would hit the same revenue base. The regulatory and geographic items are narrower, event-driven risks layered on top.
For the engine’s reasoning on PAHC’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - Specialty & Generic
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ANIP | ANI Pharmaceuticals, Inc. | 2 | 1 | 0 | 3 |
| AMLX | Amylyx Pharmaceuticals, Inc. | 2 | 0 | 0 | 2 |
| PAHC● | Phibro Animal Health Corporatio | 1 | 3 | 0 | 4 |
| AMPH | Amphastar Pharmaceuticals, Inc. | 1 | 2 | 1 | 4 |
| AMRX | Amneal Pharmaceuticals, Inc. | 1 | 1 | 0 | 2 |
| ALKS | Alkermes plc | 0 | 1 | 1 | 2 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.